US regulators have recommended pausing the use of Johnson & Johnson’s (J&J’s) Covid-19 vaccine as they investigate rare blood clotting in six women, including one who died.
J&J also said it was delaying the roll-out of its vaccine in Europe. US officials said the temporary halt is expected to last only a few days.
The move comes after Europe’s drug regulator said it had found a possible link between the Oxford-AstraZeneca Covid-19 vaccine and the very rare occurrence of blood clots in some adults who had received the shot.
Britain’s health regulator has recommended that people under the age of 30 get an alternative Covid-19 vaccine, if possible.
How worried should we be about blood clots linked to AstraZeneca and Johnson & Johnson COVID-19 vaccines? Toggle share menu
Advertisement
Advertisement World
How worried should we be about blood clots linked to AstraZeneca and Johnson & Johnson COVID-19 vaccines?
FILE PHOTO: A dose of the AstraZeneca COVID-19 vaccine is prepared in a vaccination centre at Newmarket Racecourse, amid the coronavirus disease outbreak in Newmarket, Britain March 26, 2021. REUTERS/Andrew Couldridge
14 Apr 2021 11:43PM (Updated:
14 Apr 2021 11:52PM) Share this content
Bookmark
ZURICH: US regulators have recommended pausing the use of Johnson & Johnson s COVID-19 vaccine as they investigate rare blood clotting in six women, including one who died.
Science has proved Boris Johnson wrong – vaccines are reducing deaths and cases
Study reveals stark difference in figures for elderly people who have been vaccinated compared to those who have not
Thankfully, less than 24 hours later, science had proved the Prime Minister wrong.
New research from NHS England and the University of Manchester showed the stark difference in cases, admissions and deaths for elderly people who had been vaccinated compared to those who had not.
In a large study involving more than 170,000 people, researchers had scrupulously case-matched participants to make sure the results were not skewed by underlying conditions, sex or geographical location.
7 Min Read
ZURICH (Reuters) - U.S. regulators have recommended pausing the use of Johnson & Johnson’s COVID-19 vaccine, as they investigate rare blood clotting in six women.
Syringes are prepared to administer the AstraZeneca coronavirus disease (COVID-19) vaccine at a new mass vaccination centre in WiZink sports arena in Madrid, Spain, April 9, 2021. REUTERS/Sergio Perez
J&J also said it was stopping the rollout of its vaccine in Europe.
The move comes after Europe’s drug regulator earlier this month said it had found a possible link between AstraZeneca’s COVID-19 vaccine and very rare blood clots in some adults who had received the shot.
What We Know On Blood Clots Linked To AstraZeneca, J&J Vaccines What We Know On Blood Clots Linked To AstraZeneca, J&J Vaccines With both the AstraZeneca and J&J vaccines, the reports involve extremely rare clotting, including a type of blood clot called cerebral venous sinus thrombosis that were seen in combination with low levels of blood platelets.
Most adverse cases occurred within two weeks of receiving the first vaccine jab (Representational)
Zurich:
US regulators have recommended pausing the use of Johnson & Johnson s COVID-19 vaccine, as they investigate rare blood clotting in six women.
J&J also said it was stopping the rollout of its vaccine in Europe.